Prostate Cancer: What Men Need to Know

Prostate cancer is the second most common cancer diagnosed in men in the United States, with the American Cancer Society estimating approximately 299,010 new cases in 2024 (American Cancer Society, Cancer Facts & Figures 2024). The disease develops in the prostate gland, a walnut-sized organ that sits below the bladder and produces seminal fluid. Understanding how prostate cancer is classified, detected, and treated is essential for navigating the decisions that follow a diagnosis. The full oncologyauthority.com reference library provides supporting context across all major cancer types and clinical processes.

Definition and scope

Prostate cancer arises from the epithelial cells lining the prostate gland. The vast majority of cases — roughly 99% by cell type — are adenocarcinomas, meaning they originate in glandular tissue. A small subset includes rarer histologies such as small cell carcinoma, transitional cell carcinoma, and squamous cell carcinoma, each carrying distinct prognoses and treatment implications.

The National Cancer Institute (NCI) classifies prostate cancer by its anatomical spread:

The five-year relative survival rate for localized and regional prostate cancer exceeds 99%, while the five-year survival rate for distant-stage disease is approximately 34% (NCI SEER Database). This survival gap underscores why staging at the time of diagnosis carries major prognostic weight.

From a regulatory standpoint, prostate cancer screening guidelines are subject to formal recommendations from the U.S. Preventive Services Task Force (USPSTF), which assigns PSA-based screening a Grade C recommendation for men aged 55–69 — meaning the decision is individualized (USPSTF, Prostate Cancer Screening Recommendation, 2018). The broader regulatory context for oncology shapes how screening programs are structured, covered, and communicated at the clinical level.

How it works

Prostate cancer develops when androgen signaling — primarily driven by testosterone and its more potent derivative dihydrotestosterone (DHT) — promotes unregulated cellular proliferation within prostatic epithelium. The androgen receptor (AR) pathway remains the central driver in most prostate cancers, which is why hormone therapy targeting testosterone suppression constitutes a foundational treatment strategy.

The Gleason grading system, now formalized within the Grade Group classification endorsed by the International Society of Urological Pathology (ISUP), measures how abnormal prostate cancer cells appear under a microscope compared to normal tissue. The grading structure works as follows:

  1. Grade Group 1 (Gleason ≤6): Low-grade, well-differentiated cells; typically slow-growing.
  2. Grade Group 2 (Gleason 3+4=7): Intermediate-grade; predominantly low-grade with minor high-grade component.
  3. Grade Group 3 (Gleason 4+3=7): Intermediate-grade; predominantly high-grade component dominates.
  4. Grade Group 4 (Gleason 8): High-grade disease with increased metastatic potential.
  5. Grade Group 5 (Gleason 9–10): Most aggressive pattern; poorly differentiated cells.

PSA (prostate-specific antigen), a serine protease produced by prostate epithelium, is the primary blood-based biomarker used in detection. Elevated PSA alone does not confirm malignancy — benign prostatic hyperplasia (BPH) and prostatitis also raise PSA — but PSA kinetics (velocity and doubling time) inform risk stratification. Blood tests and tumor markers explains PSA interpretation within the broader framework of oncologic laboratory evaluation.

Common scenarios

Three clinical presentations dominate prostate cancer encounters in practice:

Incidentally detected, asymptomatic disease: PSA elevation identified during routine screening in a man with no urinary symptoms. This is the most common entry point, particularly for Grade Group 1–2 cancers.

Locally advanced disease with obstructive symptoms: Men presenting with urinary hesitancy, frequency, or incomplete bladder emptying sometimes have prostate cancer as an underlying cause alongside or instead of BPH. Local extension beyond the capsule may be detected on digital rectal exam (DRE) or MRI.

Metastatic presentation: Bone pain — particularly in the spine, pelvis, or femur — is the hallmark symptom of skeletal metastases, which represent the most common site of distant spread in prostate cancer. Bone scan and PSMA PET imaging are used to identify osseous involvement.

A contrast between low-risk and high-risk presentations illustrates why individualized assessment matters:

Feature Low-Risk Profile High-Risk Profile
PSA level <10 ng/mL >20 ng/mL
Grade Group 1 4–5
Clinical stage T1–T2a T3–T4
Management consideration Active surveillance Multimodal treatment

Active surveillance — structured monitoring without immediate intervention — is endorsed by the National Comprehensive Cancer Network (NCCN) as the preferred management approach for Grade Group 1 disease in appropriate candidates (NCCN Guidelines, Prostate Cancer Version 4.2024).

Decision boundaries

The decision to treat versus monitor, and the selection of treatment modality, depends on the intersection of tumor biology, patient health status, and patient preference. Key boundary points include:

Active surveillance vs. treatment: NCCN criteria distinguish candidates for surveillance from those requiring intervention based on Grade Group, PSA density (PSA divided by prostate volume, with thresholds typically below 0.15 ng/mL/cc for surveillance candidacy), and tumor extent on biopsy.

Radical prostatectomy vs. radiation therapy: For localized disease, both radical prostatectomy and radiation therapy achieve comparable cancer control at 10 years in most comparative studies. Side effect profiles differ: surgery carries higher short-term incontinence risk; radiation carries higher long-term rectal toxicity risk. Surgical oncology provides framework context for the operative decision.

Hormone therapy integration: For high-risk localized or metastatic disease, hormone therapy for cancer — specifically androgen deprivation therapy (ADT) — is combined with radiation or systemic agents. Castration-resistant prostate cancer (CRPC), defined as progression despite serum testosterone below 50 ng/dL, requires escalation to agents such as enzalutamide or abiraterone.

Genetic testing implications: Germline mutations in BRCA1, BRCA2, and ATM are identified in approximately 12% of men with metastatic prostate cancer (Journal of Clinical Oncology, Pritchard et al., 2016). These mutations affect treatment eligibility for PARP inhibitors and carry familial risk implications. Genetic testing and cancer risk covers the evaluation pathway.

Clinical trials access: For men with advanced or resistant disease, clinical trials represent a structured pathway to novel agents, particularly PSMA-targeted radiopharmaceuticals and next-generation AR inhibitors.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)